Educational guide
Hims & Hers stock rises 14% as FDA schedules peptide ...
Quartz April 17, 2026 The U.S. Food and Drug Administration set July 23–24 advisory meetings to evaluate seven peptides for compounding eligibility, a development with implications for telehealth and consumer access.Hims & Hers Health stock rose 13.7%, with pr
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Quartz
April 17, 2026
The U.S. Food and Drug Administration set July 23–24 advisory meetings to evaluate seven peptides for compounding eligibility, a development with implications for telehealth and consumer access.Hims & Hers Health stock rose 13.7%, with premarket trading adding another 9.6% the next morning, MarketWatch reported. The FDA peptide review will cover BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon, with recommendations non-binding.Hims & Hers said peptides are a target category, and its chief medical officer called the FDA's clarity an avenue toward trusted channels. In 2023 the FDA removed 19 peptides over safety risks; supporters seek broader access while critics warn of weak evidence and threats to drug standards.